Blood Cell Kit Finally Gets Official Safety Stamp
Published Date: 10/9/2026
Rule
Summary
The FDA is officially putting the hematopoietic cell enrichment kit into Class II, meaning it now has special safety rules but fewer hurdles than the highest-risk devices. This change helps make sure the kit is safe and effective while speeding up patient access to this cool medical tech. The new classification took effect on October 9, 2026, but has been in place since November 6, 2023, so manufacturers and patients can benefit now without extra costs.
Analyzed Economic Effects
7 provisions identified: 2 benefits, 4 costs, 1 mixed.
Extensive verification and validation study requirements
Manufacturers must provide detailed design verification and validation documentation, including recovery studies, a limit-of-detection study using an FDA-acceptable flow cytometry reference, reproducibility studies with multiple operators and three reagent lots across low/medium/high target levels, specificity/interference studies, sample stability studies, on-board and in-use reagent stability, and a separate shipping‑stability study.
Device moved to Class II (easier access)
The FDA officially classified the hematopoietic cell enrichment kit as Class II (special controls). The order is effective October 9, 2026, and the classification has been applicable since November 6, 2023; FDA says this reduces regulatory burdens and will enhance patient access to the device.
Device subject to 510(k) premarket notification
FDA states that hematopoietic cell enrichment kits are subject to premarket notification under section 510(k). Manufacturers must therefore prepare and submit 510(k) filings rather than being exempt from that requirement.
Minimum performance: 95% accurate call rate requirement
The intended-use statement must list specimen types for each malignancy and document acceptable enrichment using the minimum volume required to ensure a 95 percent accurate call rate when the cell concentration is at the device limit of detection, per the device labeling.
De Novo class can serve as predicate for future devices
FDA notes the De Novo classification allows the device type to be used as a predicate for future devices, enabling other sponsors to use the less burdensome 510(k) process rather than a De Novo or premarket approval application.
Sample-collection devices must be FDA-cleared or included
Any sample collection device used with the kit must be FDA-cleared, approved, or classified as 510(k) exempt for the sample types intended, or the sample collection device must be cleared as part of the kit's premarket submission.
Labeling must include specific limiting statements (48‑hour rule)
Labeling must include detailed procedures and prominent limiting statements, including that bone marrow stability is severely compromised after 48 hours (or another FDA‑supported timeframe), that the device is only for enriching specimens for further analysis, that results do not provide information about health conditions, and that the device is not for cell enumeration.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20730, Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications; Correction
The FDA fixed a previous announcement about pulling approval for 16 generic drug applications. Three drugs from Navinta LLC—ribavirin solution, fosaprepitant powder, and nicardipine capsules—won't lose approval because Navinta asked to keep them active. This means those three drugs stay on the market, while the other 13 still had their approvals withdrawn as planned back in July 2026.
Previous / Next Documents
Previous: 2026-20722, Airworthiness Directives; Airbus Helicopters Deutschland GmbH (AHD) Helicopters
If you own or fly an Airbus Helicopters Deutschland MBB-BK 117 C-1, listen up! The FAA found a problem where a part called the louver box assembly might come loose during flight because it was installed wrong. Starting October 26, 2026, pilots and maintenance crews must regularly check this part and fix any issues to keep flights safe. This might mean some extra work and costs, but safety always comes first!
Next: 2026-20726, Medical Devices; Cardiovascular Devices; Classification of the Infant Pulse Rate and Oxygen Saturation Monitor for Over-the-Counter Use
The FDA is officially classifying infant pulse rate and oxygen saturation monitors for over-the-counter use as Class II devices with special safety rules. This change makes these monitors easier to get, safer to use, and less costly to bring to market. Starting October 9, 2026, parents and caregivers can expect better access to these helpful devices without extra red tape.